18.06.2020 16:13:10
|
Stock Alert: Protagonist Therapeutics Up 10% As Hepcidin Mimetic PTG-300 Gets Orphan Drug Status
(RTTNews) - Shares of clinical-stage biopharmaceutical company Protagonist Therapeutics, Inc. (PTGX) are rising more than 10% Thursday morning. The company said its drug candidate hepcidin mimetic PTG-300 for the treatment polycythemia vera, a rare form of blood cancer, has got Orphan Drug Designation from the FDA. Protagonist had recently announced initial positive Phase II results of PTG-300 in patients with polycythemia vera.
The stock is currently trading at $17.92, close to its 52-week high of $18.70.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Protagonist Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Protagonist Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Protagonist Therapeutics Inc | 38,49 | -0,10% |
|